Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06043700 · ClinicalTrials.gov registry record
A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology
A clinical trial of Alzheimers Disease, sponsored by Eisai Limited.
- Active
- Registry status
- 2,000
- Enrollment target
- 3
- Study locations
NCT06043700: Active study of Alzheimers Disease, sponsored by Eisai Limited.
NCT06043700 is a study of Alzheimers Disease that is active but no longer recruiting, run by Eisai Limited. The registered enrollment target is 2,000 participants, below the 4,047-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (51% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06043700, a study of Alzheimers Disease, is active but no longer recruiting, sponsored by Eisai Limited.
- ACTIVE NOT RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 3
- Study locations
Study Summary
The primary purpose of this study is to identify participants with or without symptoms of Alzheimer's Disease (AD) that are at high risk for brain amyloid pathology using blood-based biomarkers.
Conditions Studied
Interventions
- OTHER No Intervention
Study Locations (3)
Florida
- Eisai Site #3 - Clermont
- Eisai Site #1 - Lady Lake
Maryland
- Eisai Site #2 - District Heights
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2023-09-12 |
| Est. Completion | 2028-03-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06043700
The ClinicalTrials.gov registry entry for NCT06043700 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,047-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (51% lower). The listed sponsor is Eisai Limited, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 1 intervention - of which No Intervention is the first listed.
NCT06043700 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Florida, Maryland.
Frequently Asked Questions
What is clinical trial NCT06043700 about?
NCT06043700 is a clinical study titled "A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology". The primary purpose of this study is to identify participants with or without symptoms of Alzheimer's Disease (AD) that are at high risk for brain amyloid pathology using blood-based biomarkers.
What is the current status of trial NCT06043700?
This trial is currently active not recruiting. The enrollment target is 2,000 participants. The study started on 2023-09-12. Estimated completion is 2028-03-31.
What conditions does trial NCT06043700 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT06043700?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT06043700?
This trial is sponsored by Eisai Limited, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06043700 being conducted?
This trial has 3 study locations across Florida, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
RECRUITING · Phase 3
-
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
RECRUITING · Phase 2
-
University of Central Florida Music Study
RECRUITING · NA
-
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
RECRUITING · Phase 3
-
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
RECRUITING · Phase 3
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.